Patent ID: 8822488

Claim:
A composition comprising buprenorphine and a μ opioid receptor antagonist, wherein the composition is characterized by an Agonist Antagonist Activity Index (AAnAI) of between about 0.7 and about 2.2; wherein; AAnAI = [ C max ⁡ ( BUP ) / EC 50 ] [ C max ⁡ ( ANTAGONIST ) / IC 50 ] wherein, EC 50 represents the half maximal effective serum concentration of buprenorphine, expressed as nM; IC 50 represents the half maximal inhibitory concentration of the μ opioid antagonist in humans, expressed as nM; C max(BUP) represents the peak serum or plasma concentration of buprenorphine and/or a μ opioid receptor agonist metabolite of buprenorphine, expressed as nM; and C max(ANTAGONIST) represents the peak serum concentration of the μ opioid antagonist and/or a μ opioid receptor antagonist metabolite of said μ opioid antagonist, expressed as nM.